Gene therapy has become one of the most rapidly growing and promising fields in regenerative medicine. As compared to conventional medicine, gene therapy is the single-dose solution for a wide application of diseases, significantly for genetic diseases, neurological, infectious and oncological disorders. Mainly encompasses the use of a viral vector to introduce an intact gene, either directly administered into the patient body (In-vivo) or indirectly via transduction of cells before infusion into the patient body (Ex-vivo), to reconstitute, remove and modify a harmful gene variant.
The global gene therapy the market was valued at $1,049 million in 2018, and is estimated to reach $10,443 million by 2026, registering a CAGR of 33.3% from 2018 to 2026.
Factors that drive the market growth involves, (1) Increase in funding for R&D activities pertaining to gene therapy, For instance in 2018 cell and gene therapy companies raised over $981 Million in venture financing and Industry Merger and acquisition volume reached to $18.8 Billion with an increase of 26% from 2017.
(2) Increased in No. of Approved Products, By the end of Q3 2019 there are a total of 15 approved cell and gene therapy products, In 2017 FDA approved KYMRIAH®, YESCARTA®, and LUXTURNA®, In 2019 ZOLGENSMA®, ZYNTEGLO® and COLLATEGENE® get market approval in the U.S., EU and Japan respectively.
Other factors that boost the market growth involves; (3) increase in government support, (4) ethical acceptance of gene therapy for cancer treatment, (5) the rise in the prevalence of cancer and (6) an increase in awareness regarding the gene therapy.
However, the high cost associated with the treatment (KYMRIAH® cost around $475,000, and LUXTURNA® costs $425,000 per Eye) and unwanted immune responses are expected to hamper the market growth.
The report also presents detailed quantitative analysis of the current market trends and future estimations from 2018 to 2026.
The forecasts cover 2 Vector Type with 13 Sub categories, 8 Gene Type, 6 Application Type, 4 Regions and 16 Countries.
The report comes with an associated file covering quantitative data from all numeric forecasts presented in the report.
Key Findings:
The report has the following key findings:
Topics Covered:
The report covers the following topics:
Forecast Segmentation:
Market forecasts are provided for each of the following sub-markets and their categories:
1- By Vector Type
2- By Gene Type
3- By Application
4- By Region
CHAPTER 1: INTRODUCTION
1.1 REPORT DESCRIPTION 17-18
1.2 TOPICS COVERED 19
1.3 KEY MARKET SEGMENTS 20
1.4 KEY BENEFITS 21
1.5 RESEARCH METHODOLOGY 21
1.6 TARGET AUDIENCE 22
1.7 COMPANIES MENTIONED 23-25
CHAPTER 2: EXECUTIVE SUMMARY
2.1 EXECUTIVE SUMMARY 26-28
2.2 CXO PROSPECTIVE 29
CHAPTER 3: MARKET OVERVIEW
3.1 MARKET DEFINITION AND SCOPE 30
3.2 KEY FINDINGS 31
3.3 TOP INVESTMENT POCKETS 32
3.4 TOP WINNING STRATEGIES 33
3.4.1. Top winning strategies, by year, 2016-2018* 34
3.4.2. Top winning strategies, by development, 2016-2018*(%) 34
3.4.3. Top winning strategies, by company, 2016-2018* 35
3.5 TOP PLAYER POSITIONING, BY PIPELINE VOLUME, 2018 36
3.6 PORTERS FIVE FORCES ANALYSIS 37-38
3.7 MARKET DYNAMICS 39
3.6.1 Drivers 39
3.6.1.1 High investment for R&D activities pertaining to gene therapy 39
3.6.1.2 Increase in prevalence of cancer 40
3.6.1.3 Growth in awareness regarding gene therapy 40
3.6.2 Restrains 41
3.6.2.1 High cost associated with gene therapies 41
3.6.2.2 Unwanted immune responses 41
3.6.3 Opportunities 42
3.6.3.1 Untapped potential for emerging markets 42
CHAPTER 4: GENE THERAPY APPROACH
4.1 OVERVIEW 43
4.2 IN VIVO APPROACH 44
4.3 EX VIVO APPROACH 45
CHAPTER 5: GENE THERAPY MARKET, BY VECTOR TYPE
5.1 OVERVIEW 46
5.1.1 Market size and forecast 47
5.2 VIRAL VECTORS 48
5.2.1 Key market trends 49
5.2.2 Key growth factors and opportunities 49
5.2.3 Market size and forecast 50-51
5.2.4 Market size and forecast by country 52
5.2.5 Adenovirus 53
5.2.6 Lentivirus 54
5.2.7 Adeno-Associated Virus 55
5.2.8 Retrovirus 56
5.2.9 Herpes Simplex Virus 57
5.2.10 Poxvirus 58
5.2.11 Vaccinia Virus 58
5.2.12 Others 59-60
5.3 NON-VIRAL VECTORS 61
5.3.1 Key market trends 61
5.3.2 Key growth factors and opportunities 62
5.3.3 Market size and forecast 62-63
5.3.4 Market size and forecast by country 64
5.3.5 Naked Plasmid Vector 65
5.3.6 Electroporation 66-67
5.3.7 Gene Gun 68
5.3.8 Lipofection 69-70
5.3.9 Others 71-72
CHAPTER 6: GENE THERAPY MARKET, BY GENE TYPE
6.1 OVERVIEW 73
6.1.1 Market size and forecast 73-74
6.2 ANTIGEN 75
6.2.1 Market size and forecast 76
6.2.2 Market size and forecast by country 76
6.3 CYTOKINE 77-78
6.3.1 Market size and forecast 79
6.3.2 Market size and forecast by country 79
6.4 TUMOR SUPPRESSOR 80-82
6.4.1 Market size and forecast 83
6.4.2 Market size and forecast by country 83
6.5 SUICIDE 84-85
6.5.1 Market size and forecast 86
6.5.2 Market size and forecast by country 86
6.6 DEFICIENCY 87
6.6.1 Market size and forecast 88
6.6.2 Market size and forecast by country 88
6.7 GROWTH FACTORS 89-91
6.7.1 Market size and forecast 92
6.7.2 Market size and forecast by country 92
6.8 RECEPTORS 93
6.8.1 CAR T-Cell and Gene Therapy 94
6.8.3.1 Introduction and Process 94
6.8.3.2 Applications and Limitations 94-95
6.8.3.3 Approved Products and Clinical Trials 96
6.8.3.4 Market and Industry Trends 97
6.8.2 Market size and forecast 98
6.8.3 Market size and forecast by country 98
6.9 OTHERS 99
6.9.1 Market size and forecast 103
6.9.2 Market size and forecast by country 103
CHAPTER 7: GENE THERAPY MARKET, BY APPLICATION
7.1 OVERVIEW 104
7.1.1 Market size and forecast 105
7.2 ONCOLOGICAL DISORDERS 106-108
7.2.1 Market size and forecast 109
7.2.2 Market size and forecast by country 109
7.3 RARE DISEASES 110-114
7.3.1 Market size and forecast 115
7.3.2 Market size and forecast by country 115
7.4 CARDIOVASCULAR DISEASES 116
7.4.1 Market size and forecast 117
7.4.2 Market size and forecast by country 117
7.5 NEUROLOGICAL DISORDERS 118
7.5.1 Market size and forecast 119
7.5.2 Market size and forecast by country 119
7.6 INFECTIOUS DISEASE 120
7.6.1 Market size and forecast 121
7.6.2 Market size and forecast by country 121
7.7 OTHER DISEASES 122
7.7.1 Market size and forecast 123
7.7.2 Market size and forecast by country 123
CHAPTER 8: GENE THERAPY MARKET, BY REGION
8.1 OVERVIEW 124
8.1.1 Market size and forecast 124
8.2 NORTH AMERICA 125
8.2.1 Key market trends 125
8.2.2 Key growth factors and opportunities 125
8.2.3 Market size and forecast, by country 126
8.2.4 Market size and forecast, by vector type 126
8.2.5 Market size and forecast, by gene type 127
8.2.6 Market size and forecast, by application 127
8.2.6.1 U.S. market size and forecast, by vector type 128
8.2.6.2 U.S. market size and forecast, by gene type 128
8.2.6.3 U.S. market size and forecast, by application 129
8.2.6.4 Canada market size and forecast, by vector type 130
8.2.6.5 Canada market size and forecast, by gene type 130
8.2.6.6 Canada market size and forecast, by application 131
8.2.6.7 Mexico market size and forecast, by vector type 132
8.2.6.8 Mexico market size and forecast, by gene type 132
8.2.6.9 Mexico market size and forecast, by application 133
8.3 EUROPE 134
8.4.1 Key market trends 134
8.4.2 Key growth factors and opportunities 134
8.4.3 Market size and forecast, by country 135
8.4.4 Market size and forecast, by vector type 135
8.4.5 Market size and forecast, by gene type 136
8.4.6 Market size and forecast, by application 136
8.3.6.1 Germany market size and forecast, by vector type 137
8.3.6.2 Germany market size and forecast, by gene type 137
8.3.6.3 Germany market size and forecast, by application 138
8.3.6.4 France market size and forecast, by vector type 139
8.3.6.5 France market size and forecast, by gene type 139
8.3.6.6 France market size and forecast, by application 140
8.3.6.7 UK market size and forecast, by vector type 141
8.3.6.8 UK market size and forecast, by gene type 141
8.3.6.9 UK market size and forecast, by application 142
8.3.6.10 Italy market size and forecast, by vector type 143
8.3.6.11 Italy market size and forecast, by gene type 143
8.3.6.12 Italy market size and forecast, by application 144
8.3.6.13 Spain market size and forecast, by vector type 145
8.3.6.14 Spain market size and forecast, by gene type 145
8.3.6.15 Spain market size and forecast, by application 146
8.3.6.16 Rest of Europe market size and forecast, by vector type 147
8.3.6.17 Rest of Europe market size and forecast, by gene type 147
8.3.6.18 Rest of Europe market size and forecast, by application 148
8.4 ASIA-PACIFIC 149
8.4.1 Key market trends 149
8.4.2 Key growth factors and opportunities 149
8.4.3 Market size and forecast, by country 150
8.4.4 Market size and forecast, by vector type 150
8.4.5 Market size and forecast, by gene type 151
8.4.6 Market size and forecast, by application 151
8.4.6.1 Japan market size and forecast, by vector type 152
8.4.6.2 Japan market size and forecast, by gene type 152
8.4.6.3 Japan market size and forecast, by application 153
8.4.6.4 China market size and forecast, by vector type 154
8.4.6.5 China market size and forecast by gene type 154
8.4.6.6 China market size and forecast, by application 155
8.4.6.7 India market size and forecast, by vector type 156
8.4.6.8 India market size and forecast, by gene type 156
8.4.6.9 India market size and forecast, by application 157
8.4.6.10 South Korea market size and forecast, by vector type 158
8.4.6.11 South Korea market size and forecast, by gene type 158
8.4.6.12 South Korea market size and forecast, by application 159
8.4.6.13 Rest of Asia-Pacific market size and forecast, by vector type 160
8.4.6.14 Rest of Asia-Pacific market size and forecast, by gene type 160
8.4.6.15 Rest of Asia-Pacific market size and forecast, by application 161
8.5 LAMEA 162
8.5.1 Key market trends 162
8.5.2 Key growth factors and opportunities 162
8.5.3 Market size and forecast, by country 163
8.5.4 Market size and forecast, by vector type 163
8.5.5 Market size and forecast, by gene type 164
8.5.6 Market size and forecast, by application 164
8.5.6.1 Brazil market size and forecast by vector type 165
8.5.6.2 Brazil market size and forecast, by gene type 165
8.5.6.3 Brazil market size and forecast, by application 166
8.5.6.4 South Africa market size and forecast, by vector type 167
8.5.6.5 South Africa market size and forecast, by gene type 167
8.5.6.6 South Africa market size and forecast, by application 168
8.5.6.7 Rest of LAMEA market size and forecast by vector type 169
8.5.6.8 Rest of LAMEA market size and forecast, by gene type 169
8.5.6.9 Rest of LAMEA market size and forecast, by application 170
CHAPTER 9: CLINICAL TRIALS ANALYSIS & PRODUCT PROFILES
9.1 OVERVIEW 171
9.2 CLINICAL TRIALS FROM 1989 TO 2018 171
9.2.1 Clinical Trials from 1989 to 2018: Based on Vector Type 172
9.2.2 Clinical Trials from 1989 to 2018: Based on Gene Type 173
9.2.3 Clinical Trials from 1989 to 2018: Based on Application 174
9.2.4 Clinical Trials from 1989 to 2018: Based on Region 175
9.3 CLINICAL TRIALS IN 2019 176
9.4 EXPECTED APPROVALS AND PIPELINE 177-178
9.5 APPROVED PRODUCTS PROFILES 179
9.5.1 GENDICINE™ 179
9.5.2 ONCORINE® 179
9.5.3 REXIN-G® 180
9.5.4 NEOVASCULGEN® 180
9.5.5 GLYBERA® 181
9.5.6 IMLYGIC® 181
9.5.7 ZALMOXIS® 182
9.5.8 STRIMVELIS® 182
9.5.9 LUXTURNA® 183
9.5.10 KYMRIAH® 183
9.5.11 YESCARTA® 184
9.5.12 INVOSSA™ 184
9.5.13 ZOLGENSMA® 185
9.5.14 ZYNTEGLO® 185
9.5.15 COLLATEGENE® 186
CHAPTER 10: COMPANY PROFILES
10.1 KEY MARKET PLAYERS 187
10.1.1. Adaptimmune Therapeutics Plc 187-188
10.1.2. Abeona Therapeutics Inc. 189-190
10.1.3. Adverum Biotechnologies, Inc. 191-192
10.1.4. Applied Genetic Technologies Corporation 193-194
10.1.5. Arbutus Biopharma Corporation 195-196
10.1.6. Audentes Therapeutics Inc. 197
10.1.7. Avexis Inc. 198
10.1.8. Anchiano Therapeutics, Inc. 199
10.1.9. Bluebird Bio, Inc. 200-201
10.1.10. Celgene Corporation 202-203
10.1.11. CRISPR Therapeutics AG 204
10.1.12. Editas Medicine, Inc. 205
10.1.13. Gilead Sciences, Inc. (Kite Pharma, Inc.) 206-207
10.1.14. GlaxoSmithKline Plc 208-209
10.1.15. Intellia Therapeutics Inc. 210
10.1.16. Merck & Co., Inc. 211-212
10.1.17. Novartis AG 213-214
10.1.18. Regenxbio, Inc. 215-216
10.1.19. Sangamo Therapeutics, Inc. 217-218
10.1.20. Spark Therapeutics, Inc. 219-220
10.1.21. Uniqure N.V. 221-222
10.1.22. Voyager Therapeutics, Inc. 223-224
10.2 OTHER COMPANY PROFILES 225
10.2.1. 4D Molecular Therapeutics 225
10.2.2. Advantagene, Inc. 226
10.2.3. Akouos, Inc. 227
10.2.4. Allogene Therapeutics, Inc. 228
10.2.5. Amgen, Inc 229
10.2.6. American Gene Technologies International Inc. 230
10.2.7. Amicus Therapeutics, Inc. 231
10.2.8. Anges MG, Inc. 232
10.2.9. Arrowhead Pharmaceuticals, Inc. 233
10.2.10. Asklepios Biopharmaceutical, Inc. 234
10.2.11. AstraZeneca Plc 235
10.2.12. Atara Biotherapeutics, Inc. 236
10.2.13. Avrobio, Inc. 237
10.2.14. Bayer AG 238
10.2.15. Benitec Biopharma Limited 239
10.2.16. Biogen Inc. 240
10.2.17. Biomarin Pharmaceutical, Inc. 241
10.2.18. Bristol-Myers Squibb Company 242
10.2.19. Carsgen Therapeutics, Ltd 243
10.2.20. Casebia Therapeutics 244
10.2.21. Cellectis SA 245
10.2.22. Celyad SA 246
10.2.23. Curevac AG 247
10.2.24. Fibrocell Science Inc. 248
10.2.25. Freeline Therapeutics, Ltd. 249
10.2.26. Gensight Biologics S.A. 250
10.2.27. Intrexon Corporation 251
10.2.28. Oxford Biomedica Plc 252
CHAPTER 11: CONCLUSION & STRATEGIC RECOMMENDATIONS
11.1 STRATEGIC RECOMMENDATIONS 253-254
11.2 CONCLUSION 255
| Price : US$ 3500 | Date : Apr 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 129 |
| Price : US$ 3500 | Date : Apr 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 125 |
| Price : US$ 3500 | Date : Apr 2024 |
| Category : Healthcare and Pharmaceuticals | Pages : 160 |
| Price : US$ 3500 | Date : Apr 2024 |
| Category : Medical Devices | Pages : 233 |
| Price : US$ 3500 | Date : Apr 2024 |
| Category : Medical Devices | Pages : 122 |
We will be happy to help you find what you need. Please call us or write to us:
Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).
This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection
Request Sample 
Request Discount 
Inquire Before Buy
